Quick Take
Gene therapy firm REGENXBIO (RGNX) has announced an agreement to acquire Dimension Therapeutics (DMTX) for approximately $85 million in stock compensation.
Dimension is a clinical stage company focusing on gene-based treatments for OTC deficiency and has a pipeline of other AAV (adeno-associated virus) vector delivered treatment candidates which it licensed from acquirer REGENXBIO.
REGENXBIO has made an important acquisition at a steep discount to Dimension’s investment basis while receiving cash and a promising pipeline of early stage liver disease treatment candidates.
